These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 2942753)
1. Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial. van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH Microcirc Endothelium Lymphatics; 1985; 2(6):657-85. PubMed ID: 2942753 [TBL] [Abstract][Full Text] [Related]
2. The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study. van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH Int Angiol; 1987; 6(3):313-22. PubMed ID: 3329207 [TBL] [Abstract][Full Text] [Related]
3. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study. Arneklo-Nobin B; Elmér O; Akesson A Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356 [TBL] [Abstract][Full Text] [Related]
4. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial. Lukác J; Rovenský J; Tauchmannová H; Zitnan D Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837 [TBL] [Abstract][Full Text] [Related]
5. Acute effect of topical minoxidil on digital blood flow in patients with Raynaud's phenomenon. Whitmore SE; Wigley FM; Wise RA J Rheumatol; 1995 Jan; 22(1):50-4. PubMed ID: 7699682 [TBL] [Abstract][Full Text] [Related]
6. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Fries R; Shariat K; von Wilmowsky H; Böhm M Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885 [TBL] [Abstract][Full Text] [Related]
7. Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon. Seibold JR; Terregino CA J Rheumatol; 1986 Apr; 13(2):337-40. PubMed ID: 2941573 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of systemic scleroderma with ketanserin. Randomized, double-blind 6-months study of 27 cases]. Cadranel J; Blétry O; Guillevin L; Lacombe C; Fraitag B; Duloroy J; Mouthon JM; Godeau P Ann Med Interne (Paris); 1986; 137(3):260-3. PubMed ID: 3532900 [TBL] [Abstract][Full Text] [Related]
9. Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: a double blind placebo controlled trial. Wise RA; Malamet R; Wigley FM J Rheumatol; 1987 Apr; 14(2):278-83. PubMed ID: 3298649 [TBL] [Abstract][Full Text] [Related]
10. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon. Rhedda A; McCans J; Willan AR; Ford PM J Rheumatol; 1985 Aug; 12(4):724-7. PubMed ID: 3903157 [TBL] [Abstract][Full Text] [Related]
11. Digital pressure and flow measurement upon local cooling in Raynaud's disease. Effect of naftidrofuryl. Bounameaux HM; Hellemans H; Verhaege R Int Angiol; 1986; 5(1):39-44. PubMed ID: 3734514 [TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of ketanserin in essential hypertension: ketanserin versus or in combination with metoprolol. Mauersberger H J Hypertens Suppl; 1986 Apr; 4(1):S73-5. PubMed ID: 2939217 [TBL] [Abstract][Full Text] [Related]
13. Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders. Roald OK; Seem E Br Med J (Clin Res Ed); 1984 Sep; 289(6445):577-9. PubMed ID: 6432198 [TBL] [Abstract][Full Text] [Related]
14. [Nicardipine in the treatment of Raynaud's phenomenon]. Kahan A; Amor B; Menkès CJ Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):487-90. PubMed ID: 3303287 [TBL] [Abstract][Full Text] [Related]
15. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study. Finch MB; Dawson J; Johnston GD Clin Rheumatol; 1986 Dec; 5(4):493-8. PubMed ID: 3816096 [TBL] [Abstract][Full Text] [Related]
16. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker. Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603 [TBL] [Abstract][Full Text] [Related]
17. Digital vascular responses to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders. Maricq HR; Weinrich MC; Valter I; Palesch YY; Maricq JG J Rheumatol; 1996 Dec; 23(12):2068-78. PubMed ID: 8970043 [TBL] [Abstract][Full Text] [Related]
18. Reproducibility of cold provocation in patients with Raynaud's phenomenon. Wigley FM; Malamet R; Wise RA J Rheumatol; 1987 Aug; 14(4):751-5. PubMed ID: 3668980 [TBL] [Abstract][Full Text] [Related]
19. Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs. Novo S; Alaimo G; Abrignani MG; Giordano U; Avellone G; Pinto A; Adamo L; Cutietta A; Indovina A; Strano A Int J Clin Pharmacol Res; 1986; 6(3):199-211. PubMed ID: 2943685 [TBL] [Abstract][Full Text] [Related]
20. Prazosin treatment of Raynaud's phenomenon: a double blind single crossover study. Russell IJ; Lessard JA J Rheumatol; 1985 Feb; 12(1):94-8. PubMed ID: 3884807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]